Epalrestat

依帕司他

Report date: 2022/11/24 10:30:35
NME

Base Information

Drug NameEpalrestat
Drug Alias Name依帕斯他epalrestatum益帕瑞士特epalrestat益帕瑞司特 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAldose reductase inhibitors
TargetsAldose reductase
Therapy Area/IndicationsCongenital disorder of glycosylation type 1ADiabetic NeuropathiesTriple Negative Breast Neoplasms
Global Approved IndicationsDiabetic Neuropathies
Approved Indications in ChinaDiabetic Neuropathies
Original Approved Country/TerritoryJapan
Original Approved Date1992/01/21
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAlfresa PharmaYangtze River Pharmaceutical Group Jiangsu Haici Biological Pharmaceutical Co Ltd
Inactive CompaniesSun Yat-Sen UniversityMaggie's Pearl LLC
Active IndicationsDiabetic Neuropathies
Inactive IndicationsCongenital disorder of glycosylation type 1ATriple Negative Breast Neoplasms

Other Information

ATC CodeA10B
Related LinksWikipediaKEGG